Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2004-000676-13 |
Epomax (1 x / week s.c.) A dose dependency evaluation | P2 |
Completed |
Kidney Diseases |
2005-11-19 |
2022-03-12 |
Treatments |
|
2004-000678-30 |
Epomax (3 x week i.v.) A dose dependency evaluation | P2 |
Completed |
Kidney Diseases |
2005-09-01 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|